Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies
JEADV, 2021.
Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD
Read publication: JEADV 2021
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacoki...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments